全文获取类型
收费全文 | 13288篇 |
免费 | 606篇 |
国内免费 | 69篇 |
专业分类
耳鼻咽喉 | 78篇 |
儿科学 | 469篇 |
妇产科学 | 148篇 |
基础医学 | 562篇 |
口腔科学 | 122篇 |
临床医学 | 3891篇 |
内科学 | 1403篇 |
皮肤病学 | 54篇 |
神经病学 | 541篇 |
特种医学 | 152篇 |
外科学 | 1380篇 |
综合类 | 1857篇 |
预防医学 | 1693篇 |
眼科学 | 78篇 |
药学 | 1081篇 |
12篇 | |
中国医学 | 192篇 |
肿瘤学 | 250篇 |
出版年
2024年 | 14篇 |
2023年 | 303篇 |
2022年 | 651篇 |
2021年 | 776篇 |
2020年 | 693篇 |
2019年 | 778篇 |
2018年 | 710篇 |
2017年 | 487篇 |
2016年 | 432篇 |
2015年 | 475篇 |
2014年 | 1256篇 |
2013年 | 1090篇 |
2012年 | 994篇 |
2011年 | 1082篇 |
2010年 | 787篇 |
2009年 | 592篇 |
2008年 | 416篇 |
2007年 | 366篇 |
2006年 | 286篇 |
2005年 | 248篇 |
2004年 | 193篇 |
2003年 | 167篇 |
2002年 | 135篇 |
2001年 | 99篇 |
2000年 | 88篇 |
1999年 | 93篇 |
1998年 | 71篇 |
1997年 | 53篇 |
1996年 | 38篇 |
1995年 | 60篇 |
1994年 | 37篇 |
1993年 | 29篇 |
1992年 | 35篇 |
1991年 | 30篇 |
1990年 | 27篇 |
1989年 | 27篇 |
1988年 | 29篇 |
1987年 | 14篇 |
1986年 | 16篇 |
1985年 | 50篇 |
1984年 | 56篇 |
1983年 | 31篇 |
1982年 | 33篇 |
1981年 | 20篇 |
1980年 | 22篇 |
1979年 | 17篇 |
1978年 | 14篇 |
1977年 | 10篇 |
1976年 | 8篇 |
1972年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 421 毫秒
1.
目的 根据乳腺癌内分泌治疗患者的症状特征,编制适用于我国乳腺癌内分泌治疗患者的症状评估量表,并检验其信效度。方法 在文献回顾及参照现有症状评估量表的基础上编制量表初始条目池;通过2轮德尔菲专家函询,形成初始版量表;通过对11例患者的认知性访谈,对量表条目进一步修订,形成临床测试版量表。便利选取2020年7月—9月在浙江省某三级甲等肿瘤医院门诊或住院的325例乳腺癌内分泌治疗患者进行问卷调查,检验量表信效度。 结果 形成的最终版乳腺癌内分泌治疗患者症状评估量表包括33个条目,探索性因子分析提取7个公因子,累计方差贡献率为68.76%;各条目内容效度指数为0.78~1.00,量表内容效度指数为0.91;内在相关性检验结果显示,量表各维度与总量表相关系数为0.58~0.79(P<0.05);维度间相关系数为0.26~0.52(P<0.05);总量表Cronbach’s α系数为0.94,重测信度为0.95,折半信度为0.84。结论 编制的乳腺癌内分泌治疗患者症状评估量表具有良好的信效度,适用于相关人群的症状测评。 相似文献
2.
3.
4.
IntroductionWe aimed to assess, in patients with Parkinson's disease (PD), the association between obstructive sleep apnea (OSA), progression of motor dysfunction and the effect of OSA treatment.MethodsData were analysed from a prospective cohort study of idiopathic PD patients from a movement disorders clinic. Patients found to have OSA on polysomnography (apnea-hypopnea index [AHI] ≥15 events/h, OSA+) were offered treatment using continuous positive airway pressure (CPAP). CPAP+ was defined as an average ≥ 2 h/night use at each follow-up. Motor symptoms were assessed using the motor section of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (mUPDRS) and the Timed-Up-And-Go (TUG). Follow-up times were 3, 6 and 12 months. Mixed models were constructed, adjusting for age, sex, body mass index, levodopa equivalent dose and comorbidities.ResultsWe studied 67 individuals (61.2% male) of mean age 64.7 years (SD = 10.1). Baseline mUPDRS was higher in OSA+ compared to OSA- (24.5 [13.6] vs. 16.2 [7.2], p < 0.001). Motor dysfunction increased at comparable rates in OSA- and OSA+CPAP-. However, in OSA+CPAP+, mUPDRS change was significantly lower compared to OSA- (β = −0.01 vs. 0.61, p = 0.03; p = 0.12 vs. OSA+CPAP- [β = 0.39]) and TUG change was lower compared to OSA+CPAP- (β = −0.01 vs. 0.13, p = 0.002; p = 0.05 vs. OSA- [β = 0.02]).ConclusionsIn this PD cohort, OSA was associated with higher baseline mUPDRS. In those with OSA, CPAP use was associated with stabilization of motor function (mUPDRS and TUG) over 12 months. These observations support further research to clarify the role of OSA in PD pathophysiology and motor dysfunction. 相似文献
5.
6.
《Neuro-Chirurgie》2022,68(3):262-266
BackgroundThe prognosis for patients with recurrent glioblastoma (GBM) is dismal, and the question of repeat surgery at time of recurrence is common. Re-operation in the management of these patients remains controversial, as there is no randomized evidence of benefit. An all-inclusive pragmatic care trial is needed to evaluate the role of repeat resection.Methods3rGBM is a multicenter, pragmatic, prospective, parallel-group randomized care trial, with 1:1 allocation to repeat resection or standard care with no repeat resection. To test the hypothesis that repeat resection can improve overall survival by at least 3 months (from 6 to 9 months), 250 adult patients with prior resection of pathology-proven glioblastoma for whom the attending surgeon believes repeat resection may improve quality survival will be enrolled. A surrogate measure of quality of life, the number of days outside of hospital/nursing/palliative care facility, will also be compared. Centers are invited to participate without financial compensation and without contracts. Clinicians may apply to local authorities to approve an investigator-led in-house trial, using a common protocol, web-based randomization platform, and simple standardized case report forms.DiscussionThe 3rGBM trial is a modern transparent care research framework with no additional risks, tests, or visits other than what patients would encounter in normal care. The burden of proof remains on repeat surgical management of recurrent GBM, because this management has yet to be shown beneficial. The trial is designed to help patients and surgeons manage the uncertainty regarding optimal care.Clinical Trial Registrationhttp://www.clinicaltrials.gov. Unique identifier: NCT04838782. 相似文献
7.
目的运用PDCA循环的质量管理方法,改进居家养老护理文件书写质量。方法对现存的护理质量不合格项目进行原因分析、制定改进计划、组织实施、效果评价。结果改进后的居家养老护理文件书写合格率达到98%。结论通过应用PDCA循环质量管理工具进行护理质量管理,使该中心居家养老护理文件书写水平得到大幅度提高,同时促进了该中心护理管理质量的提升。 相似文献
8.
9.
10.
ObjectiveThe purpose of this paper is to review the efficacy and safety profile in children treated with topical 0.03% Tacrolimus ointment for vernal keratoconjunctivitis in Middle East and to propose a treatment posology. According to recent studies, a complex non-IgE dependent mechanism plays a relevant role in the pathogenesis of vernal keratoconjunctivitis. Numerous cells and mediators have been found in the serum, conjunctiva and tears of patients with Vernal keratoconjunctivitis.DesignThis case series included 10 patients from a single centre, pediatric department of a tertiary hospital with active symptomatic vernal keratoconjunctivitis. All the patients had proliferative lesions and corneal involvement despite conventional medications, including topical steroids. All other medications, systemic and topical: steroids, antihistamines and cyclosporine, were unsuccessful. Patients were treated with topical 0.03% Tacrolimus ointment twice daily for 8 weeks and then once a day for the next two month followed by thrice a week for two months. The changes in symptoms and signs after treatment were evaluated, also the development of possible complications was assessed.ResultsThe results showed a significant reduction in signs and symptoms after 4 weeks of the treatment. Clinical resolution of giant papillae and corneal lesions were seen within eight weeks and no additional drug was required during that period, except tear substitutes. Treatment was continued for period of two months and then slowly reduced.ConclusionThe use of 0.03% Tacrolimus ointment is safe and effective in children refractory to conventional treatment of vernal keratoconjunctivitis even in high temperature climate as Middle East. Due to the effectiveness of the treatment, the dosage used may be proposed for conventional use. 相似文献